<DOC>
	<DOCNO>NCT01295567</DOCNO>
	<brief_summary>Rationale : Due western lifestyle human coronary artery prone develop atherosclerotic plaque . Hence heart important target organ atherothrombotic complication : myocardial ischemia , arrhythmia , myocardial infarction heart failure . To alleviate symptom decrease mortality patient , myocardial revascularisation recommend . Coronary artery bypass grafting ( CABG ) indicate patient severe atherosclerotic disease three coronary artery leave main stem coronary artery . Cardiac ischemia reperfusion injury CABG inevitable jointly accountable complication occur CABG ( e.g . death , myocardial infarction , arrhythmia , stroke , renal complication ) . Dipyridamole show reduce ischemia reperfusion injury healthy volunteer use intermediate endpoint may prevent cardiovascular death event secondary prevention cerebrovascular disease . The investigator hypothesise oral pre-treatment dipyridamole increase cardiac tissue tolerance ischemia reperfusion injury due CABG . The investigator expect low troponin-I release patient pretreated dipyridamole . Objective : To study effect oral pretreatment dipyridamole high sensitivity ( HS ) -troponin-I release CABG . Secondary objectives whether oral pretreatment dipyridamole reduces postoperative CABG arrhythmia , prolong inotropic support , duration Intensive Care-stay . Further secondary endpoint effect dipyridamole pretreatment renal injury post-ischemic recovery contractile function ( measure ex-vivo ) . Hypothesis : The investigator hypothesize oral pre-treatment dipyridamole increase cardiac tissue tolerance ischemia reperfusion injury . The investigator expect low HS-troponin-I release patient pretreated dipyridamole . Additionally investigator expect incidence arrhythmia , need prolong inotropic support ( long 24 hour postoperative ) decrease pretreated patient .</brief_summary>
	<brief_title>Can Dipyridamole Induce Protection Against Ischemia Reperfusion Injury Patients Undergoing Elective Coronary Artery Bypass Grafting ( CABG ) ?</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Acceptation CABG RUNMC Informed consent Recent myocardial infarction ( STEMI nonSTEMI ) , two week prior inclusion Asthma Use insulin Use sulfonylurea derivates ( e.g . glibenclamide , tolbutamide , gliclazide , glimepiride ) Use metformin Use oral corticosteroid Use dipyridamole Use clopidogrel within 8 day prior schedule CABG surgery Chronic use Non Steroid AntiInflammatory Drugs ( NSAIDs ) Offpump surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ischemia reperfusion injury</keyword>
	<keyword>CABG</keyword>
	<keyword>dipyridamole</keyword>
	<keyword>HS-troponin-I</keyword>
</DOC>